Beyond the bedside: the pharma physician
09 Feb 2026
By Ronald Allan M. Ponteres, MD, MBAH
The role of physicians in the pharmaceutical industry has grown markedly over the past decade. No longer confined to clinical settings, doctors now contribute to an expanding range of functions that shape the development, evaluation, and responsible use of medicines. Their clinical grounding, patient‑centered judgment, and ethical orientation make them uniquely positioned to guide drug development, medical affairs, drug safety, regulatory compliance, health economics, and even corporate leadership. As pharmaceutical medicine matures into a recognized scientific discipline and medical specialty, physicians strengthen the industry’s ability to uphold accuracy, transparency, and patient‑focused decision‑making, an evolution aligned with global expectations for robust regulatory authority, real‑world evidence, and scientifically grounded engagement with healthcare systems. (Setia et al., 2018).
Roles roundup
Medical Affairs physicians are often seen as the scientific backbone of biopharmaceutical companies, making sure that all clinical information shared with healthcare professionals is accurate, balanced, and free from promotional bias. They act as a bridge between research and development and commercial teams, keeping scientific integrity while helping guide strategic decisions. Their work includes interpreting new clinical data, supporting medical education and investigator‑initiated studies, and enabling fair, peer‑to‑peer scientific discussions. As global regulators tighten supervision of promotional activities, Medical Affairs has become a key guardian of ethical, evidence‑based communication and a driver of meaningful real‑world data and health‑economic insights (Setia et al., 2018).
Clinical development is another major career path, where physicians design and oversee clinical trials from first‑in‑human studies to confirmatory and post‑approval research. Their medical expertise ensures that every study protocol is scientifically sound, feasible, and ethically responsible. This role is especially important in complex fields like oncology, immunology, rare diseases, and precision medicine, where careful medical judgment and teamwork across specialties are essential. As biologics, cell therapies, and gene‑based treatments continue to advance, clinical development specialists play a key role in integrating science, safety, and strategy to move new therapies forward effectively and responsibly (Chopra, 2025).
Drug safety is another major career path for physicians, focusing on protecting patients throughout a medicine’s entire life cycle. Pharmacovigilance doctors identify, assess, monitor, and prevent adverse drug reactions using information from clinical trials, spontaneous reports, observational studies, and global safety databases. They turn these safety data and signals into practical actions (e.g. regulatory reports, periodic updates, and risk‑minimization plans), maintaining a reasonable treatment benefit-risk profile. The role demands strong clinical judgment, a solid understanding of epidemiology and regulations, and the ability to make sense of complex data. As modern therapies become more advanced and safety expectations continue to rise, the need for skilled pharmacovigilance physicians grows, offering clinicians a meaningful way to safeguard patients and protect public health locally and globally (Edwards & Aronson, 2000; Uppsala Monitoring Centre, 2021).
Physicians are also increasingly stepping into executive leadership roles within organizations. The rise of Chief Medical Officers (CMOs) shows how essential medical governance and scientific integrity have become to long‑term business strategy. CMOs oversee medical compliance, safety systems, evidence‑generation plans, and organizational health initiatives, responsibilities that became even more critical during the COVID‑19 pandemic as companies relied on strong medical risk management for business continuity. Today, they influence regulatory engagement, employee health programs, data‑transparency efforts, and medical communications, demonstrating how physicians help shape the ethical and operational core of modern corporate practice (Myers et al., 2022).
Research highlights the unique value physicians bring to pharmaceutical medicine, especially in roles that require strong clinical and scientific judgment. Studies show that Medical Affairs Pharmaceutical Physicians (MAPPs) often have more advanced clinical and academic training than other medical affairs professionals, reflecting the level of expertise needed for high‑stakes medical decision‑making (Jandhyala, 2022). Physicians also work closely with regulators, clinicians, and patient groups, applying evidence‑driven judgment in fast‑moving and complex scientific environments. Yet many clinicians remain unfamiliar with industry career options, stressing the need for structured education and professional development programs to support successful transitions into these roles (Sweiti et al., 2019).
Smarter medicine ahead
Technological advancements, especially artificial intelligence, are reshaping the landscape of pharmaceutical medicine, and physicians remain central to this transformation. In a personal communication, Dr Maria Lizette Iñigo, a specialist in pharmaceutical medicine, emphasizes how rapidly the field is evolving in response to these innovations. She notes that “pharmaceutical medicine is changing as new technologies, such as artificial intelligence, help speed up how medicines are researched, tested, and monitored.” According to her, AI allows researchers to analyze vast amounts of data more efficiently, resulting in faster identification of promising drug candidates. While AI increases efficiency and accelerates discovery, Dr Iñigo stresses the enduring importance of medical oversight, stating that “physicians remain essential to ensure decisions are safe, ethical, and truly focused on patient needs.” She highlights that no algorithm can fully replace the clinical judgment and ethical responsibility that physicians bring to the table. AI, she explains, should be viewed as an intelligent support tool that enhances decision‑making and reduces routine workload rather than one that replaces human expertise. This synergy between technology and medicine, she adds, can ultimately lead to more precise, personalized, and effective treatments for patients. For aspiring physicians, she believes this creates unique opportunities to merge clinical expertise with innovation. In due course, Dr Iñigo sees this integration to expand the global impact of medically informed patient care.
Seeding, future‑proofing
The Philippines offers a strong example of how pharmaceutical medicine is growing as both a discipline and a profession. Since 1969, the Philippine College of Pharmaceutical Medicine (PCPM) has promoted competency, ethics, and collaboration across government, industry, and academic institutions, while aligning its standards with global organizations such as IFAPP (IFAPP, 2025). One of its major achievements is the Ateneo–PCPM Diploma in Pharmaceutical Medicine and Management (DPMM), a postgraduate program built on international competency frameworks and covering areas like drug discovery, clinical development, regulatory science, medical governance, and lifecycle management (Ateneo CCE, 2025). Through applied learning, case studies, and structured assessments, the program helps develop skilled and ethical physicians who are ready to take on meaningful roles in the pharmaceutical industry.
Dr Kristine Vistal, a diplomate of the PCPM and graduate of the DPMM program, highlights the significant value the curriculum offers to physicians pursuing careers in the pharmaceutical industry. She notes during a private correspondence that “the PCPM has helped define the core competencies expected of physicians entering the pharmaceutical industry through the Ateneo–PCPM Diploma in Pharmaceutical Medicine and Management.” She further explains that the program provides “valuable exposure to industry‑specific best practices and updates during conventions,” which supports continuous learning and professional development. For Dr Vistal, this structured training serves as a bridge between clinical expertise and practical industry application. It enhances physicians’ capabilities by introducing essential domains such as regulatory science, pharmacovigilance, ethics, and healthcare marketplace dynamics. She emphasizes that this multidisciplinary approach equips learners with both strategic insight and operational competence. Eventually, Dr Vistal believes the program prepares physicians to contribute responsibly, confidently, and meaningfully to the evolving field of pharmaceutical medicine.
Progress meets purpose
Physicians in the pharmaceutical industry play a crucial role in keeping drug development, evidence generation, and medical decision‑making both scientifically sound and ethically responsible. Their clinical experience and patient‑focused judgment strengthen every step of a medicine’s journey; from early research to real‑world use. As technology improves and healthcare continues to change, the need for medically trained professionals to guide safe and responsible innovation becomes even more important. Because with physicians in pharma, science doesn’t just advance—it moves forward with wisdom and compassion.
References:
Setia, S., Ryan, N. J., Nair, P. S., Ching, E., & Subramaniam, K. (2018). Evolving role of pharmaceutical physicians in medical evidence and education. Advances in Medical Education and Practice, 9, 777–790.
Chopra, P. (2025). Embracing medicines development as a profession. Pharmaceutical Medicine, 39, 215–224.
Myers, C. G., Polsky, D., & Desai, S. (2022). The growing role of chief medical officers in major corporations. JAMA Health Forum, 3(7), e222194.
Jandhyala, R. (2022). Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders. F1000Research, 11, 813.
Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. The Lancet, 356(9237), 1255–1259.
Uppsala Monitoring Centre. (2021). The UMC handbook: A practical guide to pharmacovigilance. Uppsala Monitoring Centre. https://www.who-umc.org/
Sweiti, H., et al. (2019). Physicians in the pharmaceutical industry: Roles, motivations, and perspectives. Drug Discovery Today, 2019 Sep;24(9):1865-1870
Ateneo Center for Continuing Education. (2025). 8th PCPM – Ateneo CCE Diploma in Pharmaceutical Medicine & Management.
International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. (2025). Philippines – Philippine College of Pharmaceutical Medicine (PCPM).
The role of physicians in the pharmaceutical industry has grown markedly over the past decade. No longer confined to clinical settings, doctors now contribute to an expanding range of functions that shape the development, evaluation, and responsible use of medicines. Their clinical grounding, patient‑centered judgment, and ethical orientation make them uniquely positioned to guide drug development, medical affairs, drug safety, regulatory compliance, health economics, and even corporate leadership. As pharmaceutical medicine matures into a recognized scientific discipline and medical specialty, physicians strengthen the industry’s ability to uphold accuracy, transparency, and patient‑focused decision‑making, an evolution aligned with global expectations for robust regulatory authority, real‑world evidence, and scientifically grounded engagement with healthcare systems. (Setia et al., 2018).
Roles roundup
Medical Affairs physicians are often seen as the scientific backbone of biopharmaceutical companies, making sure that all clinical information shared with healthcare professionals is accurate, balanced, and free from promotional bias. They act as a bridge between research and development and commercial teams, keeping scientific integrity while helping guide strategic decisions. Their work includes interpreting new clinical data, supporting medical education and investigator‑initiated studies, and enabling fair, peer‑to‑peer scientific discussions. As global regulators tighten supervision of promotional activities, Medical Affairs has become a key guardian of ethical, evidence‑based communication and a driver of meaningful real‑world data and health‑economic insights (Setia et al., 2018).
Clinical development is another major career path, where physicians design and oversee clinical trials from first‑in‑human studies to confirmatory and post‑approval research. Their medical expertise ensures that every study protocol is scientifically sound, feasible, and ethically responsible. This role is especially important in complex fields like oncology, immunology, rare diseases, and precision medicine, where careful medical judgment and teamwork across specialties are essential. As biologics, cell therapies, and gene‑based treatments continue to advance, clinical development specialists play a key role in integrating science, safety, and strategy to move new therapies forward effectively and responsibly (Chopra, 2025).
Drug safety is another major career path for physicians, focusing on protecting patients throughout a medicine’s entire life cycle. Pharmacovigilance doctors identify, assess, monitor, and prevent adverse drug reactions using information from clinical trials, spontaneous reports, observational studies, and global safety databases. They turn these safety data and signals into practical actions (e.g. regulatory reports, periodic updates, and risk‑minimization plans), maintaining a reasonable treatment benefit-risk profile. The role demands strong clinical judgment, a solid understanding of epidemiology and regulations, and the ability to make sense of complex data. As modern therapies become more advanced and safety expectations continue to rise, the need for skilled pharmacovigilance physicians grows, offering clinicians a meaningful way to safeguard patients and protect public health locally and globally (Edwards & Aronson, 2000; Uppsala Monitoring Centre, 2021).
Physicians are also increasingly stepping into executive leadership roles within organizations. The rise of Chief Medical Officers (CMOs) shows how essential medical governance and scientific integrity have become to long‑term business strategy. CMOs oversee medical compliance, safety systems, evidence‑generation plans, and organizational health initiatives, responsibilities that became even more critical during the COVID‑19 pandemic as companies relied on strong medical risk management for business continuity. Today, they influence regulatory engagement, employee health programs, data‑transparency efforts, and medical communications, demonstrating how physicians help shape the ethical and operational core of modern corporate practice (Myers et al., 2022).
Research highlights the unique value physicians bring to pharmaceutical medicine, especially in roles that require strong clinical and scientific judgment. Studies show that Medical Affairs Pharmaceutical Physicians (MAPPs) often have more advanced clinical and academic training than other medical affairs professionals, reflecting the level of expertise needed for high‑stakes medical decision‑making (Jandhyala, 2022). Physicians also work closely with regulators, clinicians, and patient groups, applying evidence‑driven judgment in fast‑moving and complex scientific environments. Yet many clinicians remain unfamiliar with industry career options, stressing the need for structured education and professional development programs to support successful transitions into these roles (Sweiti et al., 2019).
Smarter medicine ahead
Technological advancements, especially artificial intelligence, are reshaping the landscape of pharmaceutical medicine, and physicians remain central to this transformation. In a personal communication, Dr Maria Lizette Iñigo, a specialist in pharmaceutical medicine, emphasizes how rapidly the field is evolving in response to these innovations. She notes that “pharmaceutical medicine is changing as new technologies, such as artificial intelligence, help speed up how medicines are researched, tested, and monitored.” According to her, AI allows researchers to analyze vast amounts of data more efficiently, resulting in faster identification of promising drug candidates. While AI increases efficiency and accelerates discovery, Dr Iñigo stresses the enduring importance of medical oversight, stating that “physicians remain essential to ensure decisions are safe, ethical, and truly focused on patient needs.” She highlights that no algorithm can fully replace the clinical judgment and ethical responsibility that physicians bring to the table. AI, she explains, should be viewed as an intelligent support tool that enhances decision‑making and reduces routine workload rather than one that replaces human expertise. This synergy between technology and medicine, she adds, can ultimately lead to more precise, personalized, and effective treatments for patients. For aspiring physicians, she believes this creates unique opportunities to merge clinical expertise with innovation. In due course, Dr Iñigo sees this integration to expand the global impact of medically informed patient care.
Seeding, future‑proofing
The Philippines offers a strong example of how pharmaceutical medicine is growing as both a discipline and a profession. Since 1969, the Philippine College of Pharmaceutical Medicine (PCPM) has promoted competency, ethics, and collaboration across government, industry, and academic institutions, while aligning its standards with global organizations such as IFAPP (IFAPP, 2025). One of its major achievements is the Ateneo–PCPM Diploma in Pharmaceutical Medicine and Management (DPMM), a postgraduate program built on international competency frameworks and covering areas like drug discovery, clinical development, regulatory science, medical governance, and lifecycle management (Ateneo CCE, 2025). Through applied learning, case studies, and structured assessments, the program helps develop skilled and ethical physicians who are ready to take on meaningful roles in the pharmaceutical industry.
Dr Kristine Vistal, a diplomate of the PCPM and graduate of the DPMM program, highlights the significant value the curriculum offers to physicians pursuing careers in the pharmaceutical industry. She notes during a private correspondence that “the PCPM has helped define the core competencies expected of physicians entering the pharmaceutical industry through the Ateneo–PCPM Diploma in Pharmaceutical Medicine and Management.” She further explains that the program provides “valuable exposure to industry‑specific best practices and updates during conventions,” which supports continuous learning and professional development. For Dr Vistal, this structured training serves as a bridge between clinical expertise and practical industry application. It enhances physicians’ capabilities by introducing essential domains such as regulatory science, pharmacovigilance, ethics, and healthcare marketplace dynamics. She emphasizes that this multidisciplinary approach equips learners with both strategic insight and operational competence. Eventually, Dr Vistal believes the program prepares physicians to contribute responsibly, confidently, and meaningfully to the evolving field of pharmaceutical medicine.
Progress meets purpose
Physicians in the pharmaceutical industry play a crucial role in keeping drug development, evidence generation, and medical decision‑making both scientifically sound and ethically responsible. Their clinical experience and patient‑focused judgment strengthen every step of a medicine’s journey; from early research to real‑world use. As technology improves and healthcare continues to change, the need for medically trained professionals to guide safe and responsible innovation becomes even more important. Because with physicians in pharma, science doesn’t just advance—it moves forward with wisdom and compassion.
References:
Setia, S., Ryan, N. J., Nair, P. S., Ching, E., & Subramaniam, K. (2018). Evolving role of pharmaceutical physicians in medical evidence and education. Advances in Medical Education and Practice, 9, 777–790.
Chopra, P. (2025). Embracing medicines development as a profession. Pharmaceutical Medicine, 39, 215–224.
Myers, C. G., Polsky, D., & Desai, S. (2022). The growing role of chief medical officers in major corporations. JAMA Health Forum, 3(7), e222194.
Jandhyala, R. (2022). Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders. F1000Research, 11, 813.
Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. The Lancet, 356(9237), 1255–1259.
Uppsala Monitoring Centre. (2021). The UMC handbook: A practical guide to pharmacovigilance. Uppsala Monitoring Centre. https://www.who-umc.org/
Sweiti, H., et al. (2019). Physicians in the pharmaceutical industry: Roles, motivations, and perspectives. Drug Discovery Today, 2019 Sep;24(9):1865-1870
Ateneo Center for Continuing Education. (2025). 8th PCPM – Ateneo CCE Diploma in Pharmaceutical Medicine & Management.
International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. (2025). Philippines – Philippine College of Pharmaceutical Medicine (PCPM).